Stock Analysis
Zhaoke Ophthalmology First Half 2024 Earnings: CN¥0.14 loss per share (vs CN¥0.43 loss in 1H 2023)
Zhaoke Ophthalmology (HKG:6622) First Half 2024 Results
Key Financial Results
- Net loss: CN¥75.8m (loss narrowed by 68% from 1H 2023).
- CN¥0.14 loss per share (improved from CN¥0.43 loss in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Zhaoke Ophthalmology shares are up 5.1% from a week ago.
Risk Analysis
Before you take the next step you should know about the 1 warning sign for Zhaoke Ophthalmology that we have uncovered.
Valuation is complex, but we're here to simplify it.
Discover if Zhaoke Ophthalmology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:6622
Zhaoke Ophthalmology
An ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, and Hong Kong.